Journal
NEUROLOGY
Volume 80, Issue 17, Pages 1557-1564Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31828f17de
Keywords
-
Categories
Funding
- University of Arizona TRIF Imaging fellowship
- National Institute of Mental Health [RO1 MH57899]
- National Institute on Aging [9R01AG031581-10, P30 AG19610, R01AG025526]
- State of Arizona
- Advanced Research Institute for Biomedical Imaging
- Evelyn F. McKnight Brain Institute
- Banner Alzheimer's Foundation
- Mayo Clinic Foundation
- NIH (NIA)
- Mind and Life Institute
- Arizona Advanced Research Institute for Biomedical Imaging
- NIH
- Avid
- NIH/NIA
- Arizona Alzheimer's Research Consortium
- Anonymous Foundation
- Nomis Foundation
- AstraZeneca
- Avid/Eli Lilly
Ask authors/readers for more resources
Objective: To investigate whether higher fasting serum glucose levels in cognitively normal, nondiabetic adults were associated with lower regional cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer disease (AD). Methods: This is a cross-sectional study of 124 cognitively normal persons aged 64 +/- 6 years with a first-degree family history of AD, including 61 APOE epsilon 4 noncarriers and 63 carriers. An automated brain mapping algorithm characterized and compared correlations between higher fasting serum glucose levels and lower [F-18]-fluorodeoxyglucose-PET rCMRgl measurements. Results: As predicted, higher fasting serum glucose levels were significantly correlated with lower rCMRgl and were confined to the vicinity of brain regions preferentially affected by AD. A similar pattern of regional correlations occurred in the APOE epsilon 4 noncarriers and carriers. Conclusions: Higher fasting serum glucose levels in cognitively normal, nondiabetic adults may be associated with AD pathophysiology. Findings suggest that the risk imparted by higher serum glucose levels may be independent of APOE epsilon 4 status. This study raises additional questions about the role of the metabolic process in the predisposition to AD and supports the possibility of targeting these processes in presymptomatic AD trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available